AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; AndroGel for males diagnosed with symptomatic low testosterone; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production. The company was incorporated in 2012 and is based in North Chicago, Illinois.
IPO Year: 2012
Exchange: NYSE
Website: abbvie.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/14/2025 | $205.00 | Buy → Neutral | Citigroup |
| 4/22/2025 | $210.00 | Overweight | Cantor Fitzgerald |
| 12/10/2024 | $191.00 | Neutral | BofA Securities |
| 12/5/2024 | $180.00 | Outperform → Neutral | Daiwa Securities |
| 11/22/2024 | $206.00 | Market Perform → Outperform | Leerink Partners |
| 11/15/2024 | $205.00 | Outperform | Wolfe Research |
| 11/4/2024 | Hold → Buy | Argus | |
| 10/17/2024 | $203.00 | Mkt Perform | Bernstein |
| 6/5/2024 | $185.00 | Hold → Buy | HSBC Securities |
| 5/17/2024 | $200.00 | Overweight | Cantor Fitzgerald |
3 - AbbVie Inc. (0001551152) (Reporting)
4 - AbbVie Inc. (0001551152) (Issuer)
4 - AbbVie Inc. (0001551152) (Issuer)
4 - AbbVie Inc. (0001551152) (Issuer)
4 - AbbVie Inc. (0001551152) (Issuer)
4 - AbbVie Inc. (0001551152) (Issuer)
4 - AbbVie Inc. (0001551152) (Issuer)
4 - AbbVie Inc. (0001551152) (Issuer)
4 - AbbVie Inc. (0001551152) (Issuer)
4 - AbbVie Inc. (0001551152) (Issuer)
Citigroup downgraded AbbVie from Buy to Neutral and set a new price target of $205.00
Cantor Fitzgerald initiated coverage of AbbVie with a rating of Overweight and set a new price target of $210.00
BofA Securities resumed coverage of AbbVie with a rating of Neutral and set a new price target of $191.00
Daiwa Securities downgraded AbbVie from Outperform to Neutral and set a new price target of $180.00
Leerink Partners upgraded AbbVie from Market Perform to Outperform and set a new price target of $206.00
Wolfe Research initiated coverage of AbbVie with a rating of Outperform and set a new price target of $205.00
Argus upgraded AbbVie from Hold to Buy
Bernstein initiated coverage of AbbVie with a rating of Mkt Perform and set a new price target of $203.00
HSBC Securities upgraded AbbVie from Hold to Buy and set a new price target of $185.00
Cantor Fitzgerald initiated coverage of AbbVie with a rating of Overweight and set a new price target of $200.00
Submission status for ABBVIE INC's drug VYALEV (ORIG-1) with active ingredient FOSCARBIDOPA AND FOSLEVODOPA has changed to 'Approval' on 10/16/2024. Application Category: NDA, Application Number: 216962, Application Classification: Type 3 - New Dosage Form and Type 4 - New Combination
Submission status for ABBVIE INC's drug VYALEV (ORIG-1) with active ingredient FOSCARBIDOPA AND FOSLEVODOPA has changed to 'Approval' on 10/16/2024. Application Category: NDA, Application Number: 216962, Application Classification: Type 3 - New Dosage Form
Submission status for ABBVIE INC's drug SKYRIZI (SUPPL-7) with active ingredient RISANKIZUMAB-RZAA has changed to 'Approval' on 06/18/2024. Application Category: BLA, Application Number: 761262, Application Classification:
Submission status for ABBVIE INC's drug SKYRIZI (SUPPL-7) with active ingredient RISANKIZUMAB-RZAA has changed to 'Approval' on 06/20/2024. Application Category: BLA, Application Number: 761262, Application Classification:
Submission status for ABBVIE INC's drug SKYRIZI (SUPPL-29) with active ingredient RISANKIZUMAB-RZAA has changed to 'Approval' on 06/18/2024. Application Category: BLA, Application Number: 761105, Application Classification:
Submission status for ABBVIE INC's drug RINVOQ (ORIG-1) with active ingredient UPADACITINIB has changed to 'Approval' on 04/26/2024. Application Category: NDA, Application Number: 218347, Application Classification: Type 3 - New Dosage Form
Submission status for ABBVIE INC's drug RINVOQ LQ (ORIG-1) with active ingredient UPADACITINIB has changed to 'Approval' on 04/26/2024. Application Category: NDA, Application Number: 218347, Application Classification: Type 3 - New Dosage Form
Submission status for ABBVIE INC's drug SKYRIZI (SUPPL-8) with active ingredient RISANKIZUMAB-RZAA has changed to 'Approval' on 03/04/2024. Application Category: BLA, Application Number: 761262, Application Classification:
Submission status for ABBVIE INC's drug SKYRIZI (SUPPL-27) with active ingredient RISANKIZUMAB-RZAA has changed to 'Approval' on 03/04/2024. Application Category: BLA, Application Number: 761105, Application Classification:
Submission status for ABBVIE INC's drug SKYRIZI (SUPPL-32) with active ingredient RISANKIZUMAB-RZAA has changed to 'Approval' on 01/03/2024. Application Category: BLA, Application Number: 761105, Application Classification:
SCHEDULE 13G/A - AbbVie Inc. (0001551152) (Subject)
8-K - AbbVie Inc. (0001551152) (Filer)
11-K - AbbVie Inc. (0001551152) (Filer)
SD - AbbVie Inc. (0001551152) (Filer)
10-Q - AbbVie Inc. (0001551152) (Filer)
8-K - AbbVie Inc. (0001551152) (Filer)
8-K - AbbVie Inc. (0001551152) (Filer)
144 - AbbVie Inc. (0001551152) (Subject)
DEFA14A - AbbVie Inc. (0001551152) (Filer)
DEF 14A - AbbVie Inc. (0001551152) (Filer)
Select Business Owners Will Receive Access to Coaching, Mentorship, and Community During Exclusive 12-Week Virtual "Boostcamp"Additionally, 20 Entrepreneurs Will Each Receive a $20,000 Grant from BOTOX® CosmeticIRVINE, Calif., July 22, 2025 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE:ABBV), today announced the 2025 class of entrepreneurs who will participate in The Confidence Project: Empowering Women Entrepreneurs. This initiative, led by BOTOX® Cosmetic, is aimed at closing the Confidence Gap and accelerating business growth for select entrepreneurs from across the country. This year's participants were selected from a pool of applicants representing a wide range of indust
Refresh Advanced OMEGA-3 Lubricant Eye Drops are the first eye drops on the market with omega-3 fatty acids MONTREAL, July 11, 2025 /CNW/ - AbbVie (NYSE:ABBV), announced today the availability of Refresh Advanced OMEGA-3 Lubricant Eye Drops in Canada. The new, preservative-free eye drop is designed to provide rapid and long-lasting relief from dry eyes with the inclusion of natural omega-3 oil that helps lock in moisture. Proven to relieve dryness, stinging and discomfort, the Refresh Advanced OMEGA-3 Lubricant Eye Drop is the first eye drop on the market with Omega-3 fatty ac
ISB 2001 is currently in Phase 1 clinical trial in patients with relapsed/refractory multiple myeloma (R/R MM)NEW YORK and NORTH CHICAGO, Ill., July 10, 2025 /PRNewswire/ -- IGI Therapeutics SA, a wholly owned subsidiary of New York-based Ichnos Glenmark Innovation, Inc. (IGI), and AbbVie (NYSE:ABBV) today announced an exclusive licensing agreement for IGI's lead investigational asset, ISB 2001, developed using IGI's proprietary BEAT® protein platform, for oncology and autoimmune diseases. "Multispecifics including trispecific antibodies represent a bold new frontier in immuno
ISB 2001 is currently in Phase 1 clinical trial in patients with relapsed/refractory multiple myeloma (R/R MM) NEW YORK and NORTH CHICAGO, Ill., July 10, 2025 (GLOBE NEWSWIRE) -- IGI Therapeutics SA, a wholly owned subsidiary of New York-based Ichnos Glenmark Innovation, Inc. (IGI), and AbbVie (NYSE:ABBV) today announced an exclusive licensing agreement for IGI's lead investigational asset, ISB 2001, developed using IGI's proprietary BEAT® protein platform, for oncology and autoimmune diseases. "Multispecifics including trispecific antibodies represent a new frontier in immuno-oncology with the potential to deliver deeper, more durable responses by engaging multiple targets simultane
ISB 2001 is currently in Phase 1 clinical trial in patients with relapsed/refractory multiple myeloma (R/R MM)NORTH CHICAGO, Ill. and NEW YORK, July 10, 2025 /PRNewswire/ -- AbbVie (NYSE:ABBV) and IGI Therapeutics SA, a wholly owned subsidiary of New York-based Ichnos Glenmark Innovation, Inc. (IGI), today announced an exclusive licensing agreement for IGI's lead investigational asset, ISB 2001, developed using IGI's proprietary BEAT® protein platform, for oncology and autoimmune diseases. "Multispecifics including trispecific antibodies represent a new frontier in immuno-oncology with the potential to deliver deeper, more durable responses by engaging multiple targets simultaneously," said
Capstan's lead asset, CPTX2309, is a targeted lipid nanoparticle (tLNP) that delivers an mRNA encoding an anti-CD19 chimeric antigen receptor (CAR) to CD8-expressing cytotoxic T cells in vivo, and is a potential first-in-class product for treating B cell-mediated autoimmune diseasesProposed acquisition strengthens AbbVie's commitment to transforming the future of patient care with Capstan's innovative tLNP platform technologyNORTH CHICAGO, Ill. and SAN DIEGO, June 30, 2025 /PRNewswire/ -- AbbVie (NYSE:ABBV) and Capstan Therapeutics, Inc. ("Capstan"), a clinical-stage biotechnology company dedicated to advancing in vivo engineering of cells through RNA delivery using tLNPs, today announced a
SKINVIVE by JUVÉDERM® is currently approved in the U.S. as the first and only hyaluronic acid microdroplet injectable indicated to improve cheek skin smoothness. If approved, SKINVIVE by JUVÉDERM® will be the first hyaluronic acid injectable treatment option aiming to reduce neck lines.The application for indication expansion is supported by a clinical study that met all primary and secondary endpoints assessing SKINVIVE by JUVÉDERM® in adults with neck lines seeking improvement in neck appearance.1IRVINE, Calif., June 30, 2025 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE:ABBV), today announced that the U.S. Food and Drug Administration (FDA) accepted for review the supplemen
NORTH CHICAGO, Ill., June 30, 2025 /PRNewswire/ -- AbbVie (NYSE:ABBV) will announce its second-quarter 2025 financial results on Thursday, July 31, 2025, before the market opens. AbbVie will host a live webcast of the earnings conference call at 8 a.m. Central time. It will be accessible through AbbVie's Investor Relations website at investors.abbvie.com. An archived edition of the session will be available later that day. About AbbVie AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas –
NORTH CHICAGO, Ill., June 20, 2025 /PRNewswire/ -- The board of directors of AbbVie Inc. (NYSE:ABBV) today declared a quarterly cash dividend of $1.64 per share. The cash dividend is payable August 15, 2025, to stockholders of record at the close of business on July 15, 2025. Since the company's inception in 2013, AbbVie has increased its dividend by 310 percent. AbbVie is a member of the S&P Dividend Aristocrats Index, which tracks companies that have annually increased their dividend for at least 25 consecutive years. About AbbVie AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tom
TEMPLE, a Phase 3 multicenter, randomized, double-blind, head-to-head study, evaluated the tolerability, safety and efficacy of atogepant compared to topiramate for the preventive treatment of migraine in adult patients with a history of four or more migraine days per month1Atogepant met the primary endpoint of fewer treatment discontinuations attributed to adverse events versus topiramate, and all six secondary endpoints achieved statistical significance for superiority versus topiramate, demonstrating clinical efficacy1Full results from the TEMPLE study will be presented at an upcoming medical meetingNORTH CHICAGO, Ill., June 18, 2025 /PRNewswire/ -- AbbVie (NYSE:ABBV) today announced posi
SC 13G/A - AbbVie Inc. (0001551152) (Subject)
SC 13G/A - AbbVie Inc. (0001551152) (Subject)
SC 13G/A - AbbVie Inc. (0001551152) (Subject)
SC 13G/A - AbbVie Inc. (0001551152) (Subject)
SC 13G/A - AbbVie Inc. (0001551152) (Subject)
SC 13G/A - AbbVie Inc. (0001551152) (Subject)
SC 13G/A - AbbVie Inc. (0001551152) (Subject)
NORTH CHICAGO, Ill., June 30, 2025 /PRNewswire/ -- AbbVie (NYSE:ABBV) will announce its second-quarter 2025 financial results on Thursday, July 31, 2025, before the market opens. AbbVie will host a live webcast of the earnings conference call at 8 a.m. Central time. It will be accessible through AbbVie's Investor Relations website at investors.abbvie.com. An archived edition of the session will be available later that day. About AbbVie AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas –
NORTH CHICAGO, Ill., June 20, 2025 /PRNewswire/ -- The board of directors of AbbVie Inc. (NYSE:ABBV) today declared a quarterly cash dividend of $1.64 per share. The cash dividend is payable August 15, 2025, to stockholders of record at the close of business on July 15, 2025. Since the company's inception in 2013, AbbVie has increased its dividend by 310 percent. AbbVie is a member of the S&P Dividend Aristocrats Index, which tracks companies that have annually increased their dividend for at least 25 consecutive years. About AbbVie AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tom
Reports First-Quarter Diluted EPS of $0.72 on a GAAP Basis, a Decrease of 6.5 Percent; Adjusted Diluted EPS of $2.46, an Increase of 6.5 Percent; These Results Include an Unfavorable Impact of $0.13 Per Share Related to Acquired IPR&D and Milestones Expense Delivers First-Quarter Net Revenues of $13.343 Billion, an Increase of 8.4 Percent on a Reported Basis or 9.8 Percent on an Operational Basis First-Quarter Global Net Revenues from the Immunology Portfolio Were $6.264 Billion, an Increase of 16.6 Percent on a Reported Basis, or 18.1 Percent on an Operational Basis; Global Skyrizi Net Revenues Were $3.425 Billion; Global Rinvoq Net Revenues Were $1.718 Billion; Global Humira Net Revenues
NORTH CHICAGO, Ill., March 31, 2025 /PRNewswire/ -- AbbVie (NYSE:ABBV) will announce its first-quarter 2025 financial results on Friday, April 25, 2025, before the market opens. AbbVie will host a live webcast of the earnings conference call at 8 a.m. Central time. It will be accessible through AbbVie's Investor Relations website at investors.abbvie.com. An archived edition of the session will be available later that day. About AbbVie AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas in
Partnership marks AbbVie's entrance into the obesity fieldAgreement will enable the incorporation of GUB014295, an amylin peptide discovered and developed by Gubra, into AbbVie's global infrastructure for developing and commercializing therapies for patients in needNORTH CHICAGO, Ill. and HØRSHOLM, Denmark, March 3, 2025 /PRNewswire/ -- AbbVie (NYSE:ABBV) and Gubra A/S (CPSE:GUBRA), a company specializing in preclinical contract research services and peptide-based drug discovery within metabolic and fibrotic diseases, today announced a license agreement to develop GUB014295, a potential best-in-class, long-acting amylin analog for the treatment of obesity. "At AbbVie, we are focused on trans
NORTH CHICAGO, Ill., Feb. 13, 2025 /PRNewswire/ -- The board of directors of AbbVie Inc. (NYSE:ABBV) today declared a quarterly cash dividend of $1.64 per share. The cash dividend is payable May 15, 2025, to stockholders of record at the close of business on April 15, 2025. Since the company's inception in 2013, AbbVie has increased its dividend by 310 percent. AbbVie is a member of the S&P Dividend Aristocrats Index, which tracks companies that have annually increased their dividend for at least 25 consecutive years. About AbbVie AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorr
Collaboration will combine AbbVie's oncology expertise and Xilio's proprietary tumor-activation technology to develop novel immunotherapies, including masked T-cell engagersXilio to host investor conference call and webcast today at 8:30 am EST NORTH CHICAGO, Ill. and WALTHAM, Mass., Feb. 12, 2025 (GLOBE NEWSWIRE) -- AbbVie (NYSE:ABBV) and Xilio Therapeutics, Inc. (NASDAQ:XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced a collaboration and option-to-license agreement to develop novel tumor-activated, antibody-based immunotherapies, including masked T-cell engagers, leveraging X
Collaboration will combine AbbVie's oncology expertise and Xilio's proprietary tumor-activation technology to develop novel immunotherapies, including masked T-cell engagers Xilio to host investor conference call and webcast today at 8:30 am ESTNORTH CHICAGO, Ill. and WALTHAM, Mass., Feb. 12, 2025 /PRNewswire/ -- AbbVie (NYSE:ABBV) and Xilio Therapeutics, Inc. (NASDAQ:XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced a collaboration and option-to-license agreement to develop novel tumor-activated, antibody-based immunotherapies, including masked T-cell engagers, leveraging Xilio's p
Reports Full-Year Diluted EPS of $2.39 on a GAAP Basis, a Decrease of 12.1 Percent; Adjusted Diluted EPS of $10.12, a Decrease of 8.9 Percent; These Results Include an Unfavorable Impact of $1.52 Per Share Related to 2024 Acquired IPR&D and Milestones Expense Delivers Full-Year Net Revenues of $56.334 Billion, an Increase of 3.7 Percent on a Reported Basis and 4.6 Percent on an Operational Basis Full-Year Global Net Revenues from the Immunology Portfolio Were $26.682 Billion, an Increase of 2.1 Percent on a Reported Basis, or 2.9 Percent on an Operational Basis; Global Humira Net Revenues Were $8.993 Billion; Global Skyrizi Net Revenues Were $11.718 Billion; Global Rinvoq Net Revenues Were
NORTH CHICAGO, Ill., Jan. 3, 2025 /PRNewswire/ -- AbbVie (NYSE:ABBV) will announce its full-year and fourth-quarter 2024 financial results on Friday, January 31, 2025, before the market opens. AbbVie will host a live webcast of the earnings conference call at 8 a.m. Central time. It will be accessible through AbbVie's Investor Relations website at investors.abbvie.com. An archived edition of the session will be available later that day. About AbbVie AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key thera
Richard A. Gonzalez to retire from the board of directors effective July 1, 2025NORTH CHICAGO, Ill., Feb. 14, 2025 /PRNewswire/ -- AbbVie (NYSE:ABBV) today announced that its board of directors has unanimously elected chief executive officer (CEO) Robert A. Michael to assume the additional position of chairman, effective July 1, 2025. He will succeed Richard A. Gonzalez, who formerly served as AbbVie's CEO and has been chairman since the Company's formation in 2013. "I want to extend my heartfelt gratitude to Rick for his remarkable leadership and dedicated service," said Roxanne S. Austin, lead independent director. "The board and I have complete confidence in Rob, and we are fortunate to
Former ImmunoGen CFO will join Seaport to steer capital financing strategy, accounting, FP&A and investor relations PureTech Health plc (NASDAQ:PRTC, LSE: PRTC)) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company, noted that its Founded Entity, Seaport Therapeutics, ("Seaport") a biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced the appointment of Lauren White as Chief Financial Officer. An accomplished biotech financial executive, Ms. White most recently served as the Chief Financial Officer at ImmunoGen (NASDAQ:IMGN) prior to its acquisition by AbbVie (NYSE:ABBV) for $10.1 billion in 2024. T
Former ImmunoGen CFO will join Seaport to steer capital financing strategy, accounting, FP&A and investor relations Seaport Therapeutics ("Seaport or the "Company"), a clinical-stage biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced the appointment of Lauren White as Chief Financial Officer. An accomplished biotech financial executive, Ms. White most recently served as the Chief Financial Officer at ImmunoGen (NASDAQ:IMGN) prior to its acquisition by AbbVie (NYSE:ABBV) for $10.1 billion in 2024. "I am so pleased to welcome Lauren as our CFO as we progress our clinical-stage pipeline of therapeutics for the treatme
For immediate release iSTAR Medical continues to strengthen US presence with appointment of Chief Medical Officer and Vice President of Clinical Affairs WAVRE, Belgium — 4 September 2024: iSTAR Medical, a medtech company delivering breakthrough eye care solutions to patients, today announces the strengthening of its leadership team with the appointment of Richard (Rick) Beckman, M.D., as Chief Medical Officer and member of the Board, and Kristine (Kris) Curtiss as Vice President of Clinical Affairs. Rick's duties as Chief Medical Officer (CMO) will cross clinical, regulatory, and medical affairs. Additionally, he will be a member of the Board. Rick brings deep insight and experience from
Join the seven million loyal Allē Members in celebrating the second annual JUVÉDERM® Day on August 21, 2024Members receive an exclusive gift card offer and a chance to win $10,000*IRVINE, Calif., July 30, 2024 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE:ABBV), today announced the return of JUVÉDERM® Day on Wednesday, August 21. After a successful first year, JUVÉDERM® Day is back with limited time offers, savings, and exclusive deals through Allē, the Allergan Aesthetics loyalty rewards program. "JUVÉDERM® Day 2023 logged the most treatments in a single day for the brand, and our goal is to surpass that this year. During this year's event, we are providing even more exclusi
NORTH CHICAGO, Ill., July 10, 2024 /PRNewswire/ -- AbbVie (NYSE:ABBV) today announced that Roopal Thakkar, M.D. who currently serves as senior vice president, chief medical officer, global therapeutics has been appointed to the position of executive vice president, research & development and chief scientific officer. In this position, Dr. Thakkar will lead the company's global R&D organization of more than 14,000 team members across all phases of discovery and development, including therapeutics and aesthetics. "Dr. Thakkar is a physician by training with a deep commitment to innovation and patient care," said Rob Michael, chief executive officer, AbbVie. "He has an excellent track record i
Ms. Austin assumes role from Glenn F. Tilton, who will continue to serve as an independent directorNORTH CHICAGO, Ill., June 20, 2024 /PRNewswire/ -- AbbVie (NYSE:ABBV) today announced that the independent directors of the board have selected Roxanne S. Austin as lead independent director, effective July 1, 2024. Ms. Austin succeeds Glenn F. Tilton, who has served as lead independent director since 2013. Mr. Tilton will continue to serve on the AbbVie Board as an independent director. "One of AbbVie's greatest strengths is an experienced, diverse and highly independent Board of Directors committed to the highest standards of corporate governance," said Richard A. Gonzalez, chairman and chief
Allē Members Can Celebrate with Double Points and Enter for a Chance to Win $5,000IRVINE, Calif., June 6, 2024 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE:ABBV), the makers of BOTOX® Cosmetic (onabotulinumtoxinA), is celebrating 25 years of SkinMedica®. To mark this milestone anniversary, Allē Members who purchase SkinMedica® products at a participating Allē Health Care Provider or SkinMedica.com from June 1 to June 25, 2024 can earn double points* and enter for a chance to win $5,000.** "For 25 years, SkinMedica® has been delivering scientifically based skincare to patients and helping them to unlock the potential to have beautiful skin," said Jasson Gilmore, Senior Vice Pr
Join Allē Today to Start Sharing and Earning RewardsRefer a Friend by Allē Lets Consumers Earn up to $50 to Use Towards Allergan Aesthetics Products and TreatmentsIRVINE, Calif., June 4, 2024 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV), today announced the debut of Refer a Friend, a new offering from Allē, the Allergan Aesthetics Loyalty Rewards Program. Now, Allē Members can invite their friends and family to join and both parties can receive savings on Allergan Aesthetics products or treatments from brands like BOTOX® Cosmetic (onabotulinumtoxinA), the JUVÉDERM® Collection of Fillers, SKINVIVE by JUVÉDERM®, CoolSculpting®, SkinMedica®, and DiamondGlow®. "When you ar
Collaboration to leverage AbbVie's therapeutic area expertise and Tentarix's Tentacles™ platform, to develop novel multifunctional biologics against one target in oncology and another in immunologyAbbVie will receive an exclusive option to acquire the therapeutic programs following candidate nomination by TentarixNORTH CHICAGO, Ill. and SAN DIEGO, Feb. 22, 2024 /PRNewswire/ -- AbbVie Inc. (NYSE:ABBV) and Tentarix Biotherapeutics today announced a multi-year collaboration focused on the discovery and development of conditionally-active, multi-specific biologic candidates in oncology and immunology. The collaboration will integrate AbbVie's expertise in oncology and immunology with Tentarix's